MedTrace Logo

Emotional Freedom Techniques to Reduce Patient Reported Cognitive Complaints in Cancer Survivors

NCT02771028 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 121

Last updated 2022-09-09

No results posted yet for this study

Summary

The aim of this study is to further validate the CDT as a screening tool for identifying elderly cancer patients in need of a more in-depth cognitive evaluation within comprehensive geriatric assessment (CGA) and to validate the pre-defined cut-off score of ≤ 4 according to the Freund scoring system. All geriatric patients that are diagnosed with cancer will be screened by the oncology clinical nurse specialists attached to the respective multi-disciplinary clinics with the VES-13 and G8 questionnaire. Patients that screen positive, will be offered referral to the multi-disciplinary onco-geriatric program where a member of the research team will implement a full geriatric evaluation under supervision of the medical oncologist and/or geriatrician who will then formulate recommendations and might suggest referral to other health care providers. Individual results and survival data of all the patients that have given their informed consent will be registered in a database.

Conditions

  • Subjective Cognitive Complaints
  • Cancer

Interventions

BEHAVIORAL

Emotional Freedom Techniques

Sponsors & Collaborators

  • Universitair Ziekenhuis Brussel

    collaborator OTHER

  • AZ Klina

    collaborator OTHER

  • General Hospital Groeninge

    lead OTHER

Principal Investigators

  • Philip R Debruyne, MD, PhD, MSc, FRCP · AZ Groeninge

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-10-01
Primary Completion
2020-03-15
Completion
2021-03-15

Countries

  • Belgium

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02771028 on ClinicalTrials.gov